Please ensure Javascript is enabled for purposes of website accessibility

Can Inovio Recover From Its Huge Setback?

By Keith Speights - Apr 28, 2021 at 5:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It might be able to, although it won't be easy.

Inovio Pharmaceuticals (INO -6.67%) hasn't ranked among the leaders in the COVID-19 vaccine race so far. However, the small biotech has been a definite contender in the second tier of vaccine makers. Inovio hoped to separate from the pack by delivering impressive results with a planned late-stage study of its COVID-19 vaccine candidate INO-4800.

That plan just ran into a major obstacle, though. Inovio announced last Friday that the U.S. Department of Defense has decided not to fund the company's phase 3 study. The news caused the biotech stock to plunge 26%. Can Inovio recover from its huge setback?

Gloved hand holding a vaccine vial with a question mark on it

Image source: Getty Images.

Two steps back

Although some investors were excited about the potential for INO-4800 last year, there were questions about how Inovio would fund clinical studies of its COVID-19 vaccine candidate. When it announced in November 2020 that the U.S. Department of Defense agreed to fund the Innovate phase 2/3 study of INO-4800, that was widely viewed as a big step forward for the company.

But the reversal of course by the Department of Defense -- in not funding the phase 3 part of the study -- amounts to two big steps back for Inovio. In some respects, it would have been better for the company to have not secured Defense Department funding at all last year. That would have forced Inovio to find alternative sources of funding, and avoided putting it in the situation it now faces.

Things could've been worse. The Department of Defense will continue to fund the phase 2 portion of the study, which is expected to wrap up soon. Also, the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense told Inovio that the funding decision had nothing to do with the company or its vaccine program -- it was due to the "changing environment of COVID-19 with the rapid deployment of vaccines."

Plan B

So what's Inovio's "plan B" for INO-4800 now that it doesn't have funding for a U.S. late-stage study of INO-4800? It's to focus on testing primarily outside of the U.S. The company said that it plans to work with Chinese biotech Advaccine and the International Vaccine Institute (IVI) "for a predominantly ex-US global Phase 3 trial."

In January, Inovio and Advaccine announced a deal to develop and market INO-4800 in the Greater China market, which includes mainland China, Hong Kong, Macao, and Taiwan. The two companies are already working together on a phase 2 study of the COVID-19 vaccine conducted in China. Inovio has also collaborated with IVI on conducting a phase 1/2 clinical study of INO-4800 in South Korea.

Does this mean that Inovio's prospects for INO-4800 in the U.S. market have evaporated? Maybe. Even if Inovio's original plans for a late-stage study in the U.S. had moved forward, the biotech could have been too late to the party -- at least for this year.

The Department of Defense was absolutely correct that since it first agreed to fund clinical studies for Inovio's vaccine candidate, the dynamics for COVID-19 vaccines in the U.S. have shifted significantly. The United States now has supply deals in place for more than enough vaccine doses to fully immunize all Americans this year. It's even shipping doses of AstraZeneca's COVID-19 vaccine to India -- a vaccine that hasn't yet won Emergency Use Authorization in the U.S.

Can Inovio recover?

Despite its major setback, Inovio could mount a comeback. The stock has already clawed back some of its losses since the announcement of the loss of funding last week. Inovio's shares are still down more than 20%, but that may not be an insurmountable decline to make up.

Inovio could still achieve success with its international late-stage testing of INO-4800. It's possible that the company's pan-COVID-variant vaccine, INO-4802, could deliver exceptionally high efficacy against emerging coronavirus variants. Remember, too, that Inovio's pipeline includes quite a few other candidates.

Granted, the road to recovery won't be an easy one for Inovio. But it's not an impossible task.

To be clear, I don't think that Inovio is a great stock to buy right now. However, this is a company that has managed to stay in business for decades despite running into many roadblocks through the years. Inovio is down, but don't count it out.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.82 (-6.67%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.